Navigation Links
ThermoGenesis Provides Update on Fiscal 2009 Results
Date:8/6/2009

RANCHO CORDOVA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today that it expects revenues for the fiscal year ended June 30, 2009, will be in the range of $19.5-$20.0 million, subject to final audit adjustments. The Company said revenues in the fourth quarter of fiscal 2009 were impacted by several factors, including delays in customer capital equipment purchases of BioArchive(R) Systems and reduced sales of AXP(R) AutoXpress(TM) ("AXP") bag sets due to the timing of orders from GE Healthcare. These AXP orders are expected to be recovered over the next two quarters.

The Company said it expects to report a loss for the fourth quarter of fiscal 2009 in the range of $2.8-$3.3 million, subject to final audit and adjustments. Contributing to the fourth quarter results are non-recurring costs of approximately $1.6 million, including non-cash charges of approximately $0.7 million. The non-cash charges primarily include $0.3 million in reserves for costs related to a transition to an upgraded AXP device and write-downs of obsolete inventory at AXP bag set suppliers and $0.2 million of excess surgical wound care inventory reserved in connection with the planned divestiture of the CryoSeal product line.

Also included in non-recurring costs in the fourth quarter are several cash charges totaling approximately $0.9 million. These include approximately $0.2 million to support the release and launch of the Company's new Res-Q(TM) 60 BMC ("Res-Q") System, $0.4 million in costs related to AXP device and disposable design enhancements and the write down of excess inventories at former AXP manufacturers, and $0.2 million
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014 /PRNewswire/ ... company focused on gynecologic disease, announced today that ... with investors including Oracle Investment Management, Jack ... Vermillion directors. Total proceeds were $10.5 million, before ... working capital and general corporate purposes. ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... and targeting Swiss biotechnology company, Syngenta, are in the ... for pretrial proceedings. The consolidated case is In Re: ... in the U.S. District Court for the District of ... litigation (MDL) has been handed over to U.S. District ...
(Date:12/24/2014)... 23, 2014 On Friday, December ... 83, the Omnibus and Continuing Resolution Appropriations Act ... hydrocephalus a condition eligible to receive funding through ... by the Department of Defense (DoD). The Hydrocephalus ... on Capitol Hill, is celebrating this victory for ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... that the anticoagulant Clexane(R) (enoxaparin sodium injection) ... the Ministry of Health, Labour and,Welfare for ... patients,undergoing orthopaedic surgery of the lower limbs ... and hip fracture surgery., Venous thromboembolism ...
... 25 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Healthcare Conference on Wednesday, January 30, at 8:30,a.m. ... webcast of the,presentation at:, http://www.wsw.com/webcast/wa48/onxx/ , ... 15 minutes early in order to,register and download ...
... 0641-2440-45, 0641-2440-41, 0641-2450-45 and 0641-2450-41;, LOTS: 107054, 117085, 047056, 097081, ... ... 107111, DEERFIELD, Ill., Jan. 25 Baxter Healthcare,Corporation has announced the ... 30mL multi-dose vials. The company,began recalling the lots on January 17, 2008 ...
Cached Biology Technology:Clexane(R)/Lovenox(R) Approved in Japan 2Clexane(R)/Lovenox(R) Approved in Japan 3Clexane(R)/Lovenox(R) Approved in Japan 4Clexane(R)/Lovenox(R) Approved in Japan 5Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials 2
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with ... device of Apple incorporating such a feature, called ...
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... can produce as much power as today,s activated-carbon supercapacitors ... environmentally friendly byproducts. The report appears in the ... devices very similar to our batteries," said study leader ... the Illinois Sustainable Technology Center at the ...
... the herbicide atrazine and a fungal disease is particularly ... of South Florida laboratory, which has been investigating the ... Rohr said the new findings show that early-life exposure ... frogs were challenged with a chytrid fungus, a pathogen ...
... genetic code that arise from mismatched nucleotide base pairs in ... disorders. In microbes, such errors provide the basis for adaption ... these genetic errors, a small protein called MutS for ... wide range of organisms, from microbes to humans. Understanding the ...
Cached Biology News:Team uses forest waste to develop cheaper, greener supercapacitors 2Early-life exposure of frogs to herbicide increases mortality from fungal disease 2Berkeley Lab researchers get a detailed look at a DNA repair protein in action 2Berkeley Lab researchers get a detailed look at a DNA repair protein in action 3
Biotin anti-human CD164...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Biology Products: